PARIS is a transdisciplinary research project that brings together five research groups located in 4 European countries, to develop diagnostic tools and improve the treatment options for high-grade serous ovarian cancer. The expertise of the partners ranges from clinical medicine and experimental models, over single cell technology, drug screening, and artificial intelligence, to medical ethics.
DR. BENNO SCHWIKOWSKI
Computational analysis, project coordination
The Computational Systems Biomedicine lab in the Department of Computational Biology at Institut Pasteur, Paris, France, develops algorithms to detect and classify transcriptomic signatures of resistance in clinical and organoid samples, and generates computational predictions for the drugs that eliminate major resistant subpopulations.
DR. ANNA VÄHÄRAUTIO
Single cell transcriptomics
The Single-cell transcriptomics of cancer group at the University of Helsinki, Finland, measures patient-specific heterogeneity in clinical and organoid samples at the level of single cells, and contributes to the detection and classification of transcriptomic signatures.
PR. KRISTER WENNERBERG
Organoid models, drug screening
The Wennerberg Group at the Biotech Research & Innovation Centre at the University of Copenhagen, Denmark, develops experimental organoid models for ovarian cancer patient-specific heterogeneity, and experimentally screens for drugs that kill the major resistant subpopulations.
PR. LINE BJØRGE
Line Bjørge’s group at the Haukeland University Hospital in Bergen, Norway, provides expertise and knowledge about the complex clinical context in which resistant subpopulations are identified, and drugs are being used to eliminate them.
PR. EMMET MC CORMACK
Ovarian cancer models
The Translational Molecular Imaging group at the University of Bergen, Norway, provides leading-edge patient-derived xenograft models and multimodal imaging to evaluate candidate drugs against resistant subpopulations.
PR. VEIKKO LAUNIS, PHD
Professor Launis and his collaborators at the Department of Clinical Medicine at the University of Turku, Finland, provide guidance on ethical aspects, such as human dignity, genetics and ethics of clinical research, and palliative care.